Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Ovarian cancer cells often exhibit resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL).
• Elevated c-FLIP expression is a key factor contributing to TRAIL resistance in these cells.
• Chemoresistant ovarian cancer cell lines (A2780/DDP, A2780/ADR) were utilized to model treatment challenges.

Purpose of the Study:

• To investigate the sensitivity of ovarian cancer cells to TRAIL and proteasome inhibitors.
• To determine if proteasome inhibitors can overcome TRAIL resistance in ovarian cancer.
• To elucidate the mechanisms by which proteasome inhibitors sensitize cells to TRAIL.

Main Methods:

• Utilized A2780 ovarian cancer cell line and its chemoresistant derivatives.
• Assessed sensitivity to TRAIL and proteasome inhibitors (PS-341, MG132).
• Analyzed molecular changes including c-FLIP, BH3-only proteins, Bax, caspase activation, and TRAIL-R1/R2 expression.

Main Results:

• Ovarian cancer cells showed limited sensitivity to TRAIL alone, largely due to high c-FLIP.
• Proteasome inhibitors significantly induced apoptosis and enhanced TRAIL sensitivity in both chemosensitive and chemoresistant cells.
• Proteasome inhibitors damaged mitochondria, activated caspases, and upregulated TRAIL-R2, which mediated TRAIL's apoptotic effects.
• Primary ovarian cancer cells, resistant to TRAIL, became sensitive upon proteasome inhibitor treatment.

Conclusions:

• Proteasome inhibitors are effective in sensitizing ovarian cancer cells, including primary cells, to TRAIL-induced apoptosis.
• The combination of proteasome inhibitors and TRAIL demonstrates significant therapeutic potential for ovarian cancer treatment.
• Targeting TRAIL resistance pathways with proteasome inhibitors offers a promising strategy for overcoming treatment challenges in ovarian cancer.